This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Safra, T. Search for Related Content PubMed PubMed Citation Articles by Safra, T.

Cardiac Safety of Liposomal Anthracyclines

Institute of Oncology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel

Correspondence: Tamar Safra, M.D., Institute of Oncology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel 64239. Telephone: 972-3-6974831; Fax: 972-3-6974828; e-mail: safrat{at}bezeqint.net

Anthracyclines have demonstrated antitumor activity in a variety of cancers; however, irreversible cardiac damage is a major dose-limiting toxicity, restricting lifetime cumulative dose. The most successful strategy to improve the cardiac safety of anthracyclines to date involves liposomal encapsulation, which alters the tissue distribution and pharmacokinetics of these agents. The cardiac safeties of liposomal daunorubicin, liposomal doxorubicin (D-99), and pegylated liposomal doxorubicin have been studied in several clinical trials. The lack of published data comparing liposomal daunorubicin with conventional daunorubicin makes it difficult to draw meaningful conclusions regarding the relative cardiac safeties of these formulations. Studies indicate that the risk of anthracycline-induced cardiotoxicity is considerably lower with liposomal doxorubicin formulations than with conventional doxorubicin. Pegylated liposomal doxorubicin has been studied most extensively and has demonstrated the most significant reductions in risk for cardiotoxicity. Compared with conventional doxorubicin, pegylated liposomal doxorubicin has shown similar efficacy with a significantly lower incidence of cardiotoxicity and significantly fewer cardiac events. Although the long-term cardiac safety of these agents is unknown, data suggest that liposomal anthracyclines, particularly pegylated liposomal doxorubicin, may offer a significant clinical benefit for patients with higher risks for anthracycline-induced cardiotoxicity.

Key Words. Anthracyclines • Liposome • Doxorubicin • Drug toxicity • Breast neoplasms

This article has been cited by other articles:

				E Andreopoulou, D Gaiotti, E Kim, A Downey, D Mirchandani, A Hamilton, A. Jacobs, J. Curtin, and F Muggia Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil(R)): Experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer Ann. Onc., April 1, 2007; 18(4): 716 - 721. [Abstract] [Full Text] [PDF]

				J-H Chen, R Ling, Q Yao, Y Li, T Chen, Z Wang, and K-Z Li Effect of small-sized liposomal Adriamycin administered by various routes on a metastatic breast cancer model Endocr. Relat. Cancer, March 1, 2005; 12(1): 93 - 100. [Abstract] [Full Text] [PDF]

				J. O'Shaughnessy Liposomal Anthracyclines for Breast Cancer: Overview Oncologist, August 1, 2003; 8(90002): 1 - 2. [Full Text] [PDF]

				E. Rivera Liposomal Anthracyclines in Metastatic Breast Cancer: Clinical Update Oncologist, August 1, 2003; 8(90002): 3 - 9. [Abstract] [Full Text] [PDF]

				S. Campos Liposomal Anthracyclines: Adjuvant and Neoadjuvant Therapy for Breast Cancer Oncologist, August 1, 2003; 8(90002): 10 - 16. [Abstract] [Full Text] [PDF]

				A. C. Wolff Liposomal Anthracyclines and New Treatment Approaches for Breast Cancer Oncologist, August 1, 2003; 8(90002): 25 - 30. [Abstract] [Full Text] [PDF]